Key result
Bevacizumab increases thromboembolism risk ~74% vs control in NSCLC patients.
Why the study?
The contribution of bevacizumab to thromboembolism risk in NSCLC patients remains controversial and requires clarification.
Does bevacizumab increase the risk of thromboembolism in patients with non-small cell lung carcinoma?
Population
3,555 NSCLC patients from nine studies
Comparison
Bevacizumab treatment vs no bevacizumab
Design
Meta-analysis of clinical trials
Authors
Loading...
Heightens thromboembolism monitoring with bevacizumab in NSCLC; confirms elevated risk in meta-analysis.
Meta-Analysis (n=3,555)
Does bevacizumab increase the risk of thromboembolism in patients with non-small cell lung carcinoma?
Odds Ratio: 1.74 (95% CI 1.15–2.62)
Absolute Event Rate: 4.8% vs 2.9%
p-value: p=0.008
Bevacizumab, particularly at a dose of 15 mg/kg, is associated with a significantly increased risk of thromboembolism in patients with non-small cell lung cancer.
Li et al. (2018) conducted a meta-analysis in non-small cell lung carcinoma (n=3,555). Bevacizumab vs. Without bevacizumab was evaluated on thromboembolism events (OR 1.74, 95% CI 1.15-2.62, p=0.008). Bevacizumab significantly increased the risk of thromboembolism in patients with non-small cell lung carcinoma compared to control (4.8% vs 2.9%; OR 1.74; 95% CI 1.15-2.62; P=0.008).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: